The session is slated for 9:10 a.m. ET and will be broadcast live through the company’s investor relations portal. For those unable to attend the real-time stream, an archived version of the discussion will remain accessible for a period of 30 days following the event.
ADC Therapeutics CEO to Address Cantor Global Healthcare Conference
Ameet Mallik, chief executive officer of ADC Therapeutics, is scheduled to headline a fireside chat at the 2026 Cantor Global Healthcare Conference in New York. The presentation, set for September 11, will provide investors with direct insight into the company’s strategic direction and its ongoing development of antibody drug conjugates.
ADC Therapeutics continues to center its operations on ZYNLONTA, a CD19-directed antibody drug conjugate currently approved for treating relapsed or refractory diffuse large B-cell lymphoma. As the company navigates clinical trials and regulatory pathways for expanded applications, the conference appearance serves as a key touchpoint for stakeholders monitoring the firm's commercial progress and its clinical pipeline, which includes combination therapies and earlier-line treatment options.
Comments (0)
No comments yet. Be the first!